1. Home
  2. LQDA vs CSTM Comparison

LQDA vs CSTM Comparison

Compare LQDA & CSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • CSTM
  • Stock Information
  • Founded
  • LQDA 2004
  • CSTM 2010
  • Country
  • LQDA United States
  • CSTM France
  • Employees
  • LQDA N/A
  • CSTM N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • CSTM Metal Fabrications
  • Sector
  • LQDA Health Care
  • CSTM Industrials
  • Exchange
  • LQDA Nasdaq
  • CSTM Nasdaq
  • Market Cap
  • LQDA 1.9B
  • CSTM 2.1B
  • IPO Year
  • LQDA 2018
  • CSTM 2013
  • Fundamental
  • Price
  • LQDA $23.15
  • CSTM $16.13
  • Analyst Decision
  • LQDA Strong Buy
  • CSTM Hold
  • Analyst Count
  • LQDA 9
  • CSTM 1
  • Target Price
  • LQDA $32.67
  • CSTM $16.00
  • AVG Volume (30 Days)
  • LQDA 2.1M
  • CSTM 1.1M
  • Earning Date
  • LQDA 11-03-2025
  • CSTM 10-29-2025
  • Dividend Yield
  • LQDA N/A
  • CSTM N/A
  • EPS Growth
  • LQDA N/A
  • CSTM N/A
  • EPS
  • LQDA N/A
  • CSTM 0.22
  • Revenue
  • LQDA $19,322,000.00
  • CSTM $7,605,000,000.00
  • Revenue This Year
  • LQDA $424.31
  • CSTM $9.45
  • Revenue Next Year
  • LQDA $359.32
  • CSTM $4.91
  • P/E Ratio
  • LQDA N/A
  • CSTM $76.62
  • Revenue Growth
  • LQDA 30.20
  • CSTM 2.04
  • 52 Week Low
  • LQDA $9.71
  • CSTM $7.33
  • 52 Week High
  • LQDA $29.94
  • CSTM $17.34
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 48.99
  • CSTM 54.45
  • Support Level
  • LQDA $21.97
  • CSTM $16.74
  • Resistance Level
  • LQDA $24.34
  • CSTM $17.34
  • Average True Range (ATR)
  • LQDA 1.20
  • CSTM 0.77
  • MACD
  • LQDA 0.05
  • CSTM 0.09
  • Stochastic Oscillator
  • LQDA 40.98
  • CSTM 47.22

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About CSTM Constellium SE (France)

Constellium SE is engaged in the design and manufacture of rolled and extruded aluminium products, serving the packaging, aerospace, automotive, defence and other transportation and industry end-markets. The business is organized into three operating segments: the Packaging and Automotive Rolled Products segment which includes the production of rolled aluminium sheet products in European and North American facilities; the Aerospace and Transportation segment includes the production of rolled aluminium products and very limited volumes of extruded products in European and North American facilities; the Automotive Structures and Industry segment includes the production of extruded aluminium products and aluminium structural components.

Share on Social Networks: